Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin

被引:32
作者
Gottsäter, A
Anwaar, I
Lind, P
Mattiasson, I
Lindgärde, F
机构
[1] Lund Univ, Univ Hosp MAS, Dept Vasc & Renal Dis, S-20502 Malmo, Sweden
[2] Lund Univ, Univ Hosp MAS, Dept Med, S-20502 Malmo, Sweden
关键词
fibrinogen cAMP; cGMP; endothelin-1; coagulation; inflammation; cholesterol; fluvastatin;
D O I
10.1097/00001721-199904000-00004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lipid-lowering statin treatment reduces cardiovascular morbidity and mortality and improves endothelial function in patients with hypercholesterolemia. The aim of the present study was to evaluate plasma levels of fibrinogen, factor VII, and the macrophage-derived inflammatory mediator neopterin during lipid lowering. In addition, the endothelial production of platelet antiaggregatory and vasodilatory factors such as nitric oxide and prostacyclin, and vasoconstrictive factors such as endothelin-1, was assessed. Plasma fibrinogen, factor VII, endothelin-1, and the neopterin and intraplatelet nitric oxide and prostacyclin mediators cyclic 3'5'-guanosine monophosphate (cGMP) and cyclic 3'-5'-adenosine monophosphate (cAMP) were measured before and 6 months after the institution of treatment with fluvastatin in 17 patients (eight men and nine women, median age 60 years) with vascular disease and previously untreated hypercholesterolemia. After 6 months, a decrease of 1.62 mmol/l [1.26-2.18 (19%); P < 0.01] was noted in levels of total cholesterol, and a decrease of 1.70 mmol/l [1.52-230 (28%); P < 0.01] in levels of low-density lipoprotein cholesterol. Plasma levels of fibrinogen had increased [from 4.81 g/l (4.26-5.27) to 5.17 g/l (4.81-5.67); P < 0.05], whereas no significant changes had occurred in intraplatelet levels of cGMP [decrease by 0.05 pmol/10(9) platelets (-0.17 to 0.24); NS], cAMP [decrease by 0.13 pmol/10(9) platelets (-0.37 to 0.86); NS], plasma endothelin-1 [decrease by 0.05 pg/ml (-0.60 to 0.70); NS], plasma factor Vn [from 1.14 IE/ml (0.58-1.38) to 1.22 IE/ml (0.96-1.46); NS], or plasma neopterin [from 8.6 nmol/l (7.1-11.5) to 8.7 nmol/l (7.9-11.3); NS]. In conclusion, during cholesterol-lowering treatment with fluvastatin, plasma levels of fibrinogen increased whereas intraplatelet cyclic nucleotide levels and plasma endothelin-1, factor VII and neopterin levels were unchanged. Blood Coag Fibrinol 10:133-140 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 55 条
[1]   THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION [J].
ANDERSON, TJ ;
MEREDITH, IT ;
YEUNG, AC ;
FREI, B ;
SELWYN, AP ;
GANZ, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) :488-493
[2]  
[Anonymous], [No title captured]
[3]  
Anwaar I, 1996, INT ANGIOL, V15, P201
[4]   Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia [J].
Anwaar, I ;
Gottsäter, A ;
Ohlsson, K ;
Mattiasson, I ;
Lindgärde, F .
CEREBROVASCULAR DISEASES, 1998, 8 (06) :310-317
[5]   Increasing plasma neopterin and persistent plasma endothelin during follow-up after acute cerebral ischemia [J].
Anwaar, I ;
Gottsäter, A ;
Lindgärde, F ;
Mattiasson, I .
ANGIOLOGY, 1999, 50 (01) :1-8
[6]  
BATTISTINI B, 1993, LAB INVEST, V68, P600
[7]   Statins and fibrinogen [J].
Black, DM .
LANCET, 1998, 351 (9113) :1430-1430
[8]  
BRANCHI A, 1993, THROMB HAEMOSTASIS, V70, P241
[9]  
BROOKER G, 1979, ADV CYCLIC NUCLEOTID, P1
[10]  
BURSTEIN M, 1970, J LIPID RES, V11, P583